Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
Xu B, Hu X, Li W, Sun T, Shen K, Wang S, Cheng Y, Zhang Q, Cui S, Tong Z, Geng C, Song E, Huang CS, Sriuranpong V, Ngan RKC, Chia YH, Wang X, Zhao H. Xu B, et al. Among authors: geng c. Eur J Cancer. 2022 Nov;175:236-245. doi: 10.1016/j.ejca.2022.08.012. Epub 2022 Sep 22. Eur J Cancer. 2022. PMID: 36155117 Clinical Trial.
Circulating High-Molecular-Weight (HMW) Adiponectin Level Is Related with Breast Cancer Risk Better than Total Adiponectin: A Case-Control Study.
Guo MM, Duan XN, Cui SD, Tian FG, Cao XC, Geng CZ, Fan ZM, Wang X, Wang S, Jiang HC, Zhang JG, Jin F, Tang JH, Liang H, Yang ZL, Wang HB, Wang QT, Li GL, Li L, Zhu SG, Zuo WS, Liu LY, Wang L, Ma DD, Liu SC, Xiang YJ, Liu L, Ye CM, Zhou WZ, Wang F, Yu LX, Ma ZB, Yu ZG. Guo MM, et al. PLoS One. 2015 Jun 12;10(6):e0129246. doi: 10.1371/journal.pone.0129246. eCollection 2015. PLoS One. 2015. PMID: 26070203 Free PMC article.
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, Wang Y, Song E, Zhang J, Cui S, Pang D, Tang L, Lei Y, Geng C, Shao Z. Huang L, et al. Among authors: geng c. Oncotarget. 2015 Jul 30;6(21):18683-92. doi: 10.18632/oncotarget.4337. Oncotarget. 2015. PMID: 26084292 Free PMC article. Clinical Trial.
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Zhang P, et al. Among authors: geng c. Lancet Oncol. 2017 Mar;18(3):371-383. doi: 10.1016/S1470-2045(17)30088-8. Epub 2017 Feb 11. Lancet Oncol. 2017. PMID: 28209298 Clinical Trial.
Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
Li J, Wang S, Wang Y, Wang X, Wang H, Feng J, Zhang Q, Sun T, Ouyang Q, Yin Y, Liu Y, Geng C, Yan M, Jiang Z. Li J, et al. Among authors: geng c. Oncologist. 2017 Nov;22(11):1333-1338. doi: 10.1634/theoncologist.2017-0088. Epub 2017 Aug 10. Oncologist. 2017. PMID: 28798274 Free PMC article.
Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
Wang F, Liu L, Cui S, Tian F, Fan Z, Geng C, Cao X, Yang Z, Wang X, Liang H, Wang S, Jiang H, Duan X, Wang H, Li G, Wang Q, Zhang J, Jin F, Tang J, Li L, Zhu S, Zuo W, Ma Z, Zhou F, Yu L, Xiang Y, Li L, Shen S, Yu Z. Wang F, et al. Among authors: geng c. Oncologist. 2017 Dec;22(12):1431-1443. doi: 10.1634/theoncologist.2017-0148. Epub 2017 Sep 14. Oncologist. 2017. PMID: 28912152 Free PMC article.
A case-control study on risk factors of breast cancer in Han Chinese women.
Liu LY, Wang F, Cui SD, Tian FG, Fan ZM, Geng CZ, Cao XC, Yang ZL, Wang X, Liang H, Wang S, Jiang HC, Duan XN, Wang HB, Li GL, Wang QT, Zhang JG, Jin F, Tang JH, Li L, Zhu SG, Zuo WS, Yu LX, Xiang YJ, Zhou F, Li L, Zhang Q, Fu QY, Ma ZB, Gao DZ, Li YY, Liu L, Ye CM, Wang YJ, Zhou WZ, Yu ZG. Liu LY, et al. Oncotarget. 2017 Oct 9;8(57):97217-97230. doi: 10.18632/oncotarget.21743. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228605 Free PMC article.
[A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer].
Jiang ZF, Xu FR, Fan J, Li BJ, Gao JN, Hu JW, Wang XJ, Zhang YQ, Wang JH, Li F, Liu Q, Liu YH, Wang S, Wang YS, Ouyang QC, Hu B, Sun GP, Zhang Y, Zang AM, Fan PZ, Wu CP, Liu J, Zhang HW, Wang W, Hu XC, Tang LL, Zhang J, Bao YY, Geng CZ, Sun Q, Zhang F, Yin YM, Jiang HC, An YH. Jiang ZF, et al. Among authors: geng cz. Zhonghua Yi Xue Za Zhi. 2018 Apr 24;98(16):1231-1235. doi: 10.3760/cma.j.issn.0376-2491.2018.16.009. Zhonghua Yi Xue Za Zhi. 2018. PMID: 29747310 Clinical Trial. Chinese.
1,502 results